Cardiovascular Systems (CSII) Stock Price
Cardiovascular Systems Price
Over the last 18 years Cardiovascular Systems grew revenue by 37.9% annually, reaching 236.22 M USD. For Cardiovascular Systems, the net margin of -15.6% is down versus 0.8% a few years ago.
Cardiovascular Systems stock price
Details
Stock Price
ⓘHow to Read This Chart
This chart tracks the historical stock price of Cardiovascular Systems over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.
Total Return vs. Price Return
The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.
Intraday Price Data
When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how Cardiovascular Systems stock reacts to market openings, earnings releases, or breaking news throughout the trading session.
What to Look For
Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing Cardiovascular Systems's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.
| Date | Cardiovascular Systems Price |
|---|
Cardiovascular Systems Revenue, EBIT, Net Income
3 Years
5 Years
10 Years
25 Years
Max
Details
Cardiovascular Systems Income Statement, Balance Sheet, Cash Flow Statement
| REVENUEM USD |
|---|
| REVENUE GROWTH% |
| GROSS MARGIN% |
| GROSS INCOMEM USD |
| EBITM USD |
| EBIT MARGIN% |
| NET INCOMEM USD |
| NET INCOME GROWTH% |
| SHARESM |
| 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023e | 2024e | 2025e | 2026e | 2027e |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 82.00 | 103.00 | 136.00 | 181.00 | 178.00 | 204.00 | 217.00 | 248.00 | 236.00 | 258.00 | 236.00 | 255.00 | 279.00 | 327.00 | 342.00 | 349.00 |
| 5.13 | 25.61 | 32.04 | 33.09 | -1.66 | 14.61 | 6.37 | 14.29 | -4.84 | 9.32 | -8.53 | 8.05 | 9.41 | 17.20 | 4.59 | 2.05 |
| 76.83 | 76.70 | 77.21 | 78.45 | 79.78 | 80.88 | 81.57 | 80.65 | 79.24 | 76.36 | 72.88 | 72.88 | 72.88 | 72.88 | 72.88 | 72.88 |
| 63.00 | 79.00 | 105.00 | 142.00 | 142.00 | 165.00 | 177.00 | 200.00 | 187.00 | 197.00 | 172.00 | 185.85 | 203.34 | 238.32 | 249.25 | 254.36 |
| -14.00 | -22.00 | -33.00 | -32.00 | -56.00 | -1.00 | 3.00 | – | -26.00 | -11.00 | -35.00 | -27.00 | -20.00 | -12.00 | -17.00 | -22.00 |
| -17.07 | -21.36 | -24.26 | -17.68 | -31.46 | -0.49 | 1.38 | – | -11.02 | -4.26 | -14.83 | -10.59 | -7.17 | -3.67 | -4.97 | -6.30 |
| -17.00 | -23.00 | -35.00 | -33.00 | -56.00 | -1.00 | 1.00 | – | -27.00 | -13.00 | -36.00 | -26.00 | -18.00 | -11.00 | -19.00 | -23.00 |
| 54.55 | 35.29 | 52.17 | -5.71 | 69.70 | -98.21 | -200.00 | – | – | -51.85 | 176.92 | -27.78 | -30.77 | -38.89 | 72.73 | 21.05 |
| 18.00 | 22.00 | 28.00 | 32.00 | 33.00 | 32.00 | 34.00 | 34.00 | 34.00 | 39.00 | 39.00 | 39.00 | 39.00 | 39.00 | 39.00 | 39.00 |
Details
Income Statement Key Figures
ⓘRevenue and Revenue Growth
Revenue is the starting point of every income statement — it measures the total sales Cardiovascular Systems generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.
Gross Margin
Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue Cardiovascular Systems retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare Cardiovascular Systems's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.
EBIT and EBIT Margin
EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.
Net Income and Earnings Per Share (EPS)
Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.
Shares Outstanding
The total number of shares Cardiovascular Systems has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.
Analyst Estimates
The projected figures represent consensus estimates from professional analysts. Compare these forecasts against Cardiovascular Systems's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.
Cardiovascular Systems stock margins
3 Years
5 Years
10 Years
25 Years
Max
Details
Cardiovascular Systems Stock Revenue, EBIT, Earnings per Share
3 Years
5 Years
10 Years
25 Years
Max
Details
Cardiovascular Systems business model & stock analysis
Cardiovascular Systems SWOT Analysis
Strengths
Cardiovascular Systems Inc (CSI) enjoys a strong market position as a leading provider of minimally invasive treatment systems for vascular diseases. The company's flagship product, the Diamondback 360® Coronary Orbital Atherectomy System, has gained significant acceptance among physicians and hospitals. This leading market position provides CSI with a competitive advantage and opportunities for growth.
CSI has a reputation for pioneering innovative technologies in the field of cardiovascular medicine. The Diamondback 360® System, with its unique orbital atherectomy technology, allows for precise removal of plaque from coronary arteries, resulting in improved patient outcomes. This technological innovation distinguishes CSI from its competitors and contributes to its strong brand image.
Weaknesses
CSI's heavy reliance on the Diamondback 360® System for revenue generation exposes the company to risks associated with market demand fluctuations and potential regulatory hurdles. Any significant issues with this product lineup could have a substantial impact on CSI's financial performance.
While CSI has established a strong presence within the United States, its market penetration in international markets is relatively limited. This geographic limitation puts CSI at a disadvantage compared to global competitors who have a more extensive reach. Expanding into new markets could provide growth opportunities but also presents challenges related to local regulations and competitive dynamics.
Opportunities
The increasing prevalence of cardiovascular diseases worldwide provides a significant growth opportunity for CSI. As the aging population continues to grow and lifestyle factors contribute to higher rates of heart-related conditions, CSI can expand its market reach by addressing these unmet medical needs through its innovative treatment systems.
Advancements in medical technology and techniques for minimally invasive cardiovascular procedures present opportunities for CSI to develop new and improved products. By staying at the forefront of these advancements, CSI can leverage its expertise and reputation to capture a larger share of the market.
Threats
The cardiovascular medical device industry is highly competitive, with new entrants and established players constantly introducing innovative products. CSI faces the risk of losing market share to competitors who offer similar or superior treatment options. Maintaining a competitive edge through continuous innovation and strategic partnerships becomes crucial in mitigating this threat.
Regulatory agencies impose strict guidelines and approval processes for medical devices, which can delay product launches and increase compliance costs for CSI. Changes in regulatory requirements, especially if not anticipated and prepared for, can hinder the company's ability to introduce new products or expand into new markets.
Cardiovascular Systems Employees
3 Years
5 Years
10 Years
25 Years
Max
Details
Cardiovascular Systems Segments
Cardiovascular Systems Revenue by Segment
3 Years
5 Years
Max
Details
Cardiovascular Systems Revenue by Region
3 Years
5 Years
Max
Details
Cardiovascular Systems Eulerpool Fair Value
Details
Fair Value Estimate
ⓘWhat Is Fair Value?
Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.
Earnings-Based Fair Value
Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.
Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021
Revenue-Based Fair Value
Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"
Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021
Dividend-Based Fair Value
Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.
Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021
How to Use This Chart
When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.
Cardiovascular Systems historical P/E ratio, EBIT multiple, and P/S ratio
Cardiovascular Systems annual returns
Details
Annual Return
ⓘWhat This Chart Shows
This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.
Price Return
Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.
Dividend Return
Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.
What to Look For
Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.
Cardiovascular Systems shares outstanding
3 Years
5 Years
10 Years
25 Years
Max
Details
Cardiovascular Systems stock splits
Cardiovascular Systems Earnings Estimates & Surprises
| Date | EPS estimate | EPS Actual | Revenue Estimate | Price reaction | Quarterly report |
|---|---|---|---|---|---|
| 7/31/2023 | -0.10USD | - | 71.74 MUSD | - | 2023 Q4 |
| 5/2/2023 | -0.15USD | - | 66.25 MUSD | - | 2023 Q3 |
| 2/1/2023 | -0.16USD | - | 63.97 MUSD | - | 2023 Q2 |
| 11/3/2022 | -0.23USD | - | 60.03 MUSD | - | 2023 Q1 |
| 8/2/2022 | -0.22USD | - | 63.91 MUSD | - | 2022 Q4 |
| 5/4/2022 | -0.29USD | - | 58.24 MUSD | - | 2022 Q3 |
| 2/3/2022 | -0.14USD | - | 64.12 MUSD | - | 2022 Q2 |
| 11/9/2021 | -0.12USD | - | 65.24 MUSD | - | 2022 Q1 |
| 8/4/2021 | -0.17USD | - | 69.86 MUSD | - | 2021 Q4 |
| 5/6/2021 | -0.10USD | - | 64.06 MUSD | - | 2021 Q3 |
Cardiovascular Systems shareholder structure
| % | Name |
|---|---|
17.71541% | |
7.40449% | |
7.23779% | |
5.95999% | |
4.37134% | |
3.46744% |
Cardiovascular Systems Beneficial Ownership Filings (SEC 13D/G)
| Stake | Holder | Filing |
|---|---|---|
17.30% | SEC ↗ | |
14.31% | SEC ↗ | |
12.00% | SEC ↗ | |
12.00% | SEC ↗ | |
12.00% | SEC ↗ | |
11.00% | SEC ↗ | |
11.00% | SEC ↗ | |
11.00% | SEC ↗ | |
11.00% | SEC ↗ | |
11.00% | SEC ↗ |
Cardiovascular Systems Executives and Management Board
14 members · avg. age 55 · 14 % women
Mr. Scott Ward (62)
Chairman of the Board, President, Chief Executive Officer · since 2013
4.34 M USD
Management
Mr. Jeffrey Points (45)
Chief Financial Officer
Mr. Alexander Rosenstein (50)
General Counsel, Corporate Secretary
Ms. Sandra Sedo (58)
Chief Compliance Officer
Mr. John Hastings (42)
Executive Vice President - Operations and Technology
Mr. Stephen Rempe (49)
Chief Human Resource Officer
Mr. Jack Nielsen
Vice President - Investor Relations and Corporate Communications
Board of Directors
Mr. Augustine Lawlor (70)
Independent Director
Ms. Martha Aronson (55)
Independent Director
Mr. Stephen Stenbeck (61)
Independent Director
Mr. Erik Paulsen (57)
Independent Director
Dr. William Cohn (62)
Independent Director
Dr. Sachin Jain (41)
Independent Director
Frequently asked questions about Cardiovascular Systems
The business model of Cardiovascular Systems Inc (CSI) is focused on developing and commercializing innovative solutions for treating peripheral and coronary artery diseases. CSI specializes in developing and manufacturing medical devices that address complex vascular diseases through its unique orbital atherectomy technology. This technology allows for precise removal of plaque in arterial vessels, restoring blood flow and improving patient outcomes. CSI's business model revolves around providing effective and minimally invasive treatment options to healthcare professionals, while continually investing in research and development to drive future growth and enhance patient care.
Cardiovascular Systems Inc primarily operates in the medical device industry, specifically focusing on the treatment of peripheral arterial disease (PAD). As a leading medical technology company, Cardiovascular Systems Inc develops and sells innovative solutions to healthcare professionals, specializing in minimally invasive treatment options for patients with PAD. With a strong presence in the cardiovascular field, Cardiovascular Systems Inc continues to make significant advancements in improving patient outcomes and quality of life.
The main competitors of Cardiovascular Systems Inc in the market are Medtronic, Boston Scientific Corporation, Abbott Laboratories, and AngioDynamics Inc.
Cardiovascular Systems Inc (CSI) is a renowned medical device company specializing in developing and commercializing innovative solutions for treating vascular diseases. Established in 1989, CSI has been at the forefront of revolutionizing the field of interventional cardiology. From humble beginnings in Minnesota, the company has grown to become a global leader in providing cutting-edge technologies for treating complex calcium and arterial plaque build-up. With a strong commitment to improving patient outcomes, CSI offers a range of products such as orbital atherectomy systems and coronary, peripheral, and vascular support devices. Through continuous research and development, CSI remains dedicated to advancing cardiovascular care worldwide.
Cardiovascular Systems Inc has achieved significant milestones in its journey. Some noteworthy achievements include the FDA clearance of its Diamondback 360® System for treating coronary artery disease, the successful completion of the ORBIT II clinical trial, and the introduction of its Diamondback Predator 360® for the peripheral artery disease market. Furthermore, the company has consistently expanded its product portfolio, focusing on innovative technologies and enhancing patient outcomes. Cardiovascular Systems Inc has also received recognition and accolades for its contributions to the medical device industry, establishing itself as a trusted name in the field of cardiovascular care.
Cardiovascular Systems Inc (CSI) is primarily present in the United States. As a leading medical device company focused on treating peripheral and coronary artery disease, CSI operates in various states across the U.S. including Arizona, California, Florida, Georgia, Illinois, New York, Texas, and many more. With its innovative solutions and dedicated medical professionals, CSI has expanded its presence throughout the country, offering its advanced technologies and therapies to healthcare providers and patients alike.
Cardiovascular Systems Inc (CSI) represents values of excellence, innovation, and patient-centric care. As a leading medical device company, CSI focuses on developing and commercializing innovative solutions for treating peripheral and coronary arterial diseases. With a mission to improve patient outcomes and quality of life, CSI is guided by a corporate philosophy rooted in continuous research, clinical evidence, and collaboration with healthcare professionals. By offering cutting-edge technologies and therapeutic strategies, CSI strives to revolutionize the field of cardiovascular medicine.
12 analysts currently rate the Cardiovascular Systems stock: 0 recommend buying, 7 holding and 5 selling.
The Cardiovascular Systems share (CSII) is listed on 3 stock exchanges, including: NASDAQ (CSII), Frankfurt (R7Y1.F), München (R7Y1.MU).
The company Cardiovascular Systems Inc (CSI) is a medical technology company specializing in innovative solutions for the treatment of vascular diseases. CSI's mission is to provide patients worldwide with a better quality of life through advanced technologies and therapeutic solutions. CSI offers a wide range of products and services to treat various vascular diseases. The main products include Orbital Atherectomy Systems (OAS), equipped with razor-sharp diamond crowns to remove calcifications and plaques from blocked arteries and improve blood flow. OAS systems are also used to treat severe cases of peripheral arterial disease (PAD) and coronary heart disease (CHD). CSI also provides a variety of training and support services to help doctors and medical professionals familiarize themselves with OAS systems and other products. The training includes practical instructions, live webinars, and hands-on workshops led by experienced healthcare professionals. Another important area of CSI's business is research and development of new products and technologies to continuously develop innovative solutions for the treatment of vascular diseases. The company has a worldwide network of research centers and clinics that collaborate closely with leading medical technology companies, university hospitals, and medical research groups. CSI works closely with health authorities and medical societies to ensure that all products and services meet the highest standards of patient safety and effectiveness. The company has obtained approvals and certifications from various regulatory agencies worldwide, including the FDA, the European Union, and the Japanese health authority. CSI's business model is based on providing highly innovative solutions for the treatment of vascular diseases and collaborating with doctors, medical professionals, and researchers to improve patient care. The company has a strong presence in the US and Europe and is now expanding to other parts of the world such as Asia, Australia, and Latin America. Overall, CSI offers an extensive portfolio of products and services for the treatment of vascular diseases and has established itself as one of the leading companies in this field. Through continuous innovation, collaboration with professionals, and adhering to the highest standards of safety and effectiveness, CSI strives to improve healthcare for patients worldwide.
The revenue cannot currently be calculated for Cardiovascular Systems.
The profit cannot currently be calculated for Cardiovascular Systems.
The P/E ratio cannot be calculated for Cardiovascular Systems at the moment.
The P/S cannot be calculated for Cardiovascular Systems currently.
The Eulerpool Quality Score for Cardiovascular Systems is 2/10.
The ISIN of Cardiovascular Systems is US1416191062. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The WKN of Cardiovascular Systems is A0RF8V. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.
The ticker of Cardiovascular Systems is CSII. The ticker symbol is used to trade Cardiovascular Systems shares on the stock exchange.
Cardiovascular Systems is assigned to the 'Health' sector.
The dividends of Cardiovascular Systems are distributed in USD.
Cardiovascular Systems stock
Cardiovascular Systems Peer Group
Cardiovascular Systems Ticker
Cardiovascular Systems FIGI
All fundamentals and in-depth analysis of Cardiovascular Systems
Our stock analysis for Cardiovascular Systems stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Cardiovascular Systems. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.